In the top June M&A by deal value, Novartis entered into an agreement to acquire Chinook Therapeutics for $3.5bn. Founded in 2019, Chinook is developing precision medicines for rare, severe chronic kidney diseases. The company's lead clinical program, atrasentan, is an endothelin A receptor antagonist that was in-licensed from AbbVie in 2019. The Phase III ALIGN trial of atrasentan is currently enrolling patients with IgA nephropathy and the Phase II AFFINITY trial of atrasentan is currently enrolling patients with proteinuric glomerular diseases. Chinook’s diversified pipeline of programs for rare, severe chronic kidney diseases will expand the Novartis renal portfolio, complementing its existing pipeline. Financing reached $7.2bn in biopharma, $458m in device, and $110m in diagnostics.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?